)
Jeffrey Martin
Founder and investor strategy partner for early-stage biotech,
Flyte Bio
United States
I am a biotech commercialization and investor strategy consultant who helps early-stage life science companies raise capital.
Sessions
-
10-Feb-2026Phacilitate.TV StudioNKILT Therapeutics: next gen cell therapy to more cancer patients
-
10-Feb-2026Phacilitate.TV StudioBeyond Viability: Designing Cryopreservation Systems for Cell Therapy
-
10-Feb-2026Phacilitate.TV StudioStrategic Foundation: Why Commercial Ready Manufacturing Should Be Considered from Day One
-
10-Feb-2026Phacilitate.TV StudioBeyond Raw Materials: Building Partnerships That Drive Cell Therapy Innovation
-
10-Feb-2026Phacilitate.TV StudioPure Proven Precise Solutions
-
10-Feb-2026Phacilitate.TV StudioLimula: a platform to streamline cell therapy manufacturing, from R&D to the clinic
-
10-Feb-2026Phacilitate.TV StudioIntroducing aiMOS: AI-Driven Media Optimization for Cell Therapy
-
10-Feb-2026Phacilitate.TV StudioBreaking the Bottleneck: Solving Late-Stage AAV Challenges with Real World Commercial Experience
-
11-Feb-2026Theatre 1Building Scalable Cell Therapy Workflows: Media, Process, and Automation in Action
-
11-Feb-2026Theatre 5Bio2Bedside Podcast live at Advanced Therapies Week - Leading Responsibly in Right-To-Try Legislation